[Peak follicular estradiol (E2) levels and midluteal progesterone/E2 ratios in ongoing pregnancies and nonconception cycles after ovulation induced with gonadotropins].
We assessed the predictive value of peak follicular estradiol (E2) levels and progesterone/E2 ratios at the time of implantation (midluteal phase) in cycles resulting in pregnancies and in nonconception cycles after ovulation induced by hMG. hMG, administered to 31 consecutive patients with ovulatory dysfunction, resulted in 13 conception and 27 nonconception cycles. It was started on day 5 of the cycle and continued until at least 1 follicle was > 18 mm and E2 levels exceeded 300 pg/ml, when HCG, 100,000 IU, was administered. Baseline hormonal profile, peak follicular E2, serum E2, progesterone levels 7 days after hCG administration, and progesterone/E2 ratios were compared between ongoing pregnancies and during nonconception cycles. There was a significant difference in peak follicular E2 levels between ongoing pregnancies and nonconception cycles (means +/- SD: 1453 +/- 580 to 1176 +/- 275, pg/ml, p < 0.05). The length of follicular phase and the number of hMG ampules administered were similar in both groups. There was no difference in midluteal progesterone/E2 ratios (131 +/- 16.9 vs 124 +/- 27.5). E2 levels the day of hCG administration were higher in cycles leading to pregnancies. We conclude that mean midluteal progesterone/E2 ratios cannot be used to predict the outcome of cycles after ovulation induction with hMG.
Ellenbogen
A
A
Dept. of Obstetrics and Gneycology, Hillel Yaffe Medical Center, Hadera.
David
H
H
Libal
Y
Y
Ballas
S
S
D000328:Adult; D006063:Chorionic Gonadotropin / Q000627:therapeutic use*; D003687:Dehydroepiandrosterone / Q000031:analogs & derivatives / Q000097:blood; D019314:Dehydroepiandrosterone Sulfate; D004958:Estradiol / Q000097:blood*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005498:Follicular Phase / Q000097:blood / Q000187:drug effects; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000188:drug therapy; D008183:Luteal Phase / Q000097:blood* / Q000187:drug effects; D007986:Luteinizing Hormone / Q000097:blood; D010060:Ovulation / Q000187:drug effects; D010062:Ovulation Induction; D011247:Pregnancy / Q000097:blood*; D011374:Progesterone / Q000097:blood*; D011388:Prolactin / Q000097:blood; D013739:Testosterone / Q000097:blood; D013997:Time Factors
D006063:Chorionic Gonadotropin; D013739:Testosterone; D003687:Dehydroepiandrosterone; D011374:Progesterone; D004958:Estradiol; D019314:Dehydroepiandrosterone Sulfate; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone